In bladder and gastric cancers, GRHL2 acts as a tumor suppressor by directly repressing ZEB1 mRNA expression [20,27], while in breast, ovarian, and colorectal cancers, GRHL2 has been shown to induce resistance to apoptosis by downregulating the death receptor FAS [29], demonstrating tumor-specific roles for GRHL2. Here, FAS is linked to neoplasm.